Observation of the efficacy and toxicity of cisplatin combined with gemcitabine or docetaxel for advanced non-small cell lung cancer
Zhou Lei
Abstract：Objective To observe the efficacy and toxicity of cisplatin combined with gemcitabine or docetaxel in the treatment of advanced non-small cell lung cancer (NSCLC).Methods In Zhoushan Hospital from January 2009 to March 2012 120 patients were randomly divided into the group GP(gemcitabine ± cisplatin) and group DP(docetaxel ± cisplatin),each with 60 cases.Two groups were treated with cisplatin 30 mg/m2,intravenous drip,days 1-3; group GP received gemcitabine 1 000 mg/m2,intravenous infusion of 30 min,days 1,8;group DP was treated with docetaxel 75 mg/m2,intravenous infusion of 60 min,day 1.21 d for 1 cycle,a total of 2 cycles of chemotherapy.The efficacy and toxicity reaction were evaluated.Results The 2 groups had no complete remission.In group GP and group NP,over all remission rate was 41.7％ (25/60) and 43.3％ (26/60),no significant difference (P ＞ 0.05).In group GP,the decrease of white blood cells,muscle soreness was significantly lower than that in group DP,the difference was statistically significant [the decrease of white blood cells:63.3％ (38/60) vs 81.7％ (49/60),muscle soreness:0 vs 31.7％ (19/60),P ＜0.05] ; thrombopeny,rash was significantly higher than that in group DP,the difference was statistically significance [thrombopeny:73.3％ (44/60) vs 33.3 ％ (20/60),rash:36.7％ (22/60) vs 0,P ＜ 0.05].Conclusion Cisplatin has the short-term effect of dual drug chemotherapy combined with gemcitabine or docetaxel; the emphasis of toxicity during chemotherapy,the toxicity should be targeted with observation,prevention and treatment.
Keywords：Cancer,non-small cell lungCisplatinGemcitabineDocetaxel
Publication Date：2014-04-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 497-499 )